86 episodes

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

Beyond Biotech - the podcast from Labiotech Labiotech

    • News

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

    Transforming treatments for epilepsy

    Transforming treatments for epilepsy

    After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. 
    One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the tide. 


    Rapport creates precision neuromedicines that act only in the brain regions where disease originates, avoiding the side effects that affect many of today’s treatments.

    This week, we have a conversation with Rapport CEO Abe Ceesay, about the company’s transformational approach, and about what’s new in neuromedicine.

    00:45-02:43: About Rapport
    02:43-05:01: What attracted you to Rapport?
    05:01-09:13: What are the issues in developing drugs in neuroscience?
    09:13-12:09: What are the areas with unmet needs?
    12:09-16:24: What are receptor-associated proteins?
    16:24-19:25: How do you avoid side-effects?
    19:25-20:35: Are other companies working in this space?
    20:35-23:49: How do you approach designing treatments for different conditions?
    23:49-26:10: Where is Rapport currently with clinical trials?
    26:10-28:26: How do you define success in your trials?
    28:26-30:27: Is your treatment used in conjunction with others?
    30:27-32:45: How is your treatment administered?
    32:45-36:10: Why is there increased interest in developing drugs for neurological disorders?
    36:10-38:20: Looking to the future
    38:20-40:44: What are the next steps for Rapport?

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

    Stay updated by subscribing to our newsletter

    • 41 min
    How does AI assist drug discovery?

    How does AI assist drug discovery?

    Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.
    A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. 

    The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process?

    This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more.

    00:58-05:11: About Insilico Medicine
    05:11-06:09: Why is AI in the news?
    06:09-07:39: Helping people through AI
    07:39-09:10: What is Insilico Medicine doing with AI?
    09:10-10:15: Does Insilico Medicine take drugs from idea to trials?
    10:15-11:32: How do your partnerships come about?
    11:32-19:34: How does drug development start with AI?
    19:34-24:43: Can AI address undruggable targets?
    24:43-25:05: What do you need to do after finding a potential drug?
    25:05-27:57: Can quantum computing aid drug development?
    27:57-30:13: How can AI help reduce costs and save time?
    30:13-32:56: What is your partnership with the University of Toronto?
    32:56-36:24: What is the timescale for introducing drugs from AI?
    36:24-37:29: What conditions are you working on?

    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

    Stay updated by subscribing to our newsletter

    • 38 min
    Biosimilars and what’s new in cell and gene therapies

    Biosimilars and what’s new in cell and gene therapies

    This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health.

    The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and what’s new at Advanced Therapies Week.
    00:40-02:30: About Cardinal Health
    02:30-05:12: What is Cardinal Health’s role in industry?
    05:12-06:11: What are the challenges of logistics?
    06:11-07:20: How important is innovation to Cardinal Health?
    07:20-12:26: How can Cardinal Health help to reduce costs?
    12:26-13:08: Keeping up with global healthcare
    13:08-19:46: How do you stay in touch with what’s new in drug discovery?
    19:46-22:07: Biosimilars Report
    22:07-27:15: What is the current state of the cell and gene therapy space?
    27:15-29:57: Are there interesting recent advances in the cell and gene therapy?
    29:57-33:38: Advanced Therapies Week
    33:38-36:40: What trends are you expecting in 2024?


    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter

    • 37 min
    BioSenic developing severe knee osteoarthritis treatment

    BioSenic developing severe knee osteoarthritis treatment

    BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. 
    The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA). 
    This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco.  
    00:52-03:19: About BioSenic
    03:19-07:34: What is osteoarthritis?
    07:34-11:45: What is ALLOB?
    11:45-15:03: What is JTA-004?
    15:04-17:14: What will you be presenting at the OARSI event? 
    17:14-20:20: How useful is attending events for BioSenic?
    20:20-21:04: How often will JTA-004 need to be administered?
    21:04-24:08: Are other companies working on osteoarthritis?
    24:08-26:26: What stage are your arsenic trioxide trails at?
    26:26-29:50: Will this be useful in treating other autoimmune diseases?
    29:50-31:08: What are the next steps?
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter

    • 31 min
    Boosting fertility by changing the vaginal microbiome

    Boosting fertility by changing the vaginal microbiome

    Freya Biosciences is a clinical-stage biotech company dedicated to reimagining women's health and redefining fertility for those previously deprived of options. 
    With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions.


    The company recently received $38 million Series A financing to advance the clinical development of its lead drug candidate, an investigational vaginal microbial immunotherapeutic. The treatment is to address infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART). 


    This week’s conversation is with Freya chief science officer and co-founder Johan van Hylckama Vlieg.


    00:58-01:55: About Freya Biosciences
    01:55-07:12: What is the vaginal microbiome?
    07:12-08:11: Are there differences between individuals’ vaginal microbiomes?
    08:11-10:20: Does this make treatments challenging?
    10:20-15:33: How does your platform use immunotherapy on the microbiome?
    15:33-16:51: How does the vaginal microbiome change following treatment?
    16:51-18:14: What happens to the vaginal microbiome of unsuccessful treatments?
    18:14-20:10: How is success measured?
    20:10-21:51: Could this lead to treatments of other conditions?
    21:51-22:51: Does the vaginal microbiome change during menopause?
    22:51-25:05: What are your clinical trials?
    25:05-26:25: Does your treatment work better in combination with others?
    26:25-27:36: Is it easy to find patients for trials?
    27:36-30:14: How are the treatments manufactured?
    30:14-31:55: How important is your recent funding?


    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 


    Stay updated by subscribing to our newsletter

    • 32 min
    Epic Bio - gene editing without cutting DNA

    Epic Bio - gene editing without cutting DNA

    Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA.

    The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. 
    This week, we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR.
    01:15-02:51: Dr Xi’s background
    02:51-05:11: The beginning of Epic Bio
    05:12-09:23: What is epigenetic editing?
    09:23-10:47: What is the Gene Expression Modulation System?
    10:47-12:47: How is the editing reversible?
    12:47-18:01: How will epigenetic editing advance treatments?
    18:01-21:24: Tackling multiple conditions
    21:24-22:46: How will your platform tackle FSHD?
    22:46-24:18: FSHD clinical trial
    24:18-25:51: How will you address costs?
    25:51-27:18: Are other companies working on epigenetics?
    27:18-29:27: What else is in the pipeline?
    29:27-31:58: What are the next steps?
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter

    • 32 min

Top Podcasts In News

The New York Times
NPR
The Daily Wire
Crooked Media
SiriusXM
Cumulus Podcast Network | Dan Bongino

You Might Also Like

Matt Pillar
Timmerman Report
STAT
Andreessen Horowitz
Stanford Engineering
Biotech 2050